About biolife solutions - BLFS
BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.
BLFS At a Glance
BioLife Solutions, Inc.
3303 Monte Villa Parkway
Bothell, Washington 98021
| Phone | 1-425-402-1400 | Revenue | 96.21M | |
| Industry | Medical Specialties | Net Income | -14,919,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 16.972% | |
| Fiscal Year-end | 12 / 2026 | Employees | 155 | |
| View SEC Filings |
BLFS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 12.001 |
| Price to Book Ratio | 3.134 |
| Price to Cash Flow Ratio | 57.40 |
| Enterprise Value to EBITDA | 300.515 |
| Enterprise Value to Sales | 11.263 |
| Total Debt to Enterprise Value | 0.017 |
BLFS Efficiency
| Revenue/Employee | 620,735.484 |
| Income Per Employee | -96,251.613 |
| Receivables Turnover | 12.098 |
| Total Asset Turnover | 0.237 |
BLFS Liquidity
| Current Ratio | 5.943 |
| Quick Ratio | 4.631 |
| Cash Ratio | 3.87 |
BLFS Profitability
| Gross Margin | 64.289 |
| Operating Margin | -1.124 |
| Pretax Margin | -12.556 |
| Net Margin | -15.506 |
| Return on Assets | -2.984 |
| Return on Equity | -3.366 |
| Return on Total Capital | -3.112 |
| Return on Invested Capital | -3.238 |
BLFS Capital Structure
| Total Debt to Total Equity | 4.812 |
| Total Debt to Total Capital | 4.592 |
| Total Debt to Total Assets | 4.379 |
| Long-Term Debt to Equity | 2.866 |
| Long-Term Debt to Total Capital | 2.734 |